China Temporarily Bans Certain Foreigners From Entry
Client Alert | 1 min read | 03.27.20
On March 26, 2020, the Ministry of Foreign Affairs of the People’s Republic of China (“MFA”) announced a decision to temporarily suspend entry into China by foreign nationals holding valid visas or residence permits (including APEC Business Travel Cards) as a preventative measure against the COVID-19 pandemic starting from midnight, March 28, 2020.
The announcement lists the specific categories of visas affected (above). However, those who enter with the visas listed below will not be affected:
- Diplomatic, service, courtesy or C visas.
- Entry with new visas, specifically those issued after this announcement.
Meanwhile, the MFA has confirmed that foreign nationals affected may apply for new visas at Chinese embassies or consulates for necessary economic, trade, scientific or technological activities or based on emergency humanitarian need.
The announcement does not indicate the expiration date of the suspension. According to the MFA, the suspension is a temporary measure that China is compelled to take considering the pandemic and the varied practices of other countries. The measures will be calibrated in view of the evolving situation and revised or updated accordingly.
Because some employees with valid work permits may not be able to enter China from March 28 due to the suspension, employers will need to prepare to make alternative work arrangements for expat workers who may be trying to return to China.
For the text of the official announcement from MFA, please go to:
Contacts
Insights
Client Alert | 5 min read | 04.23.26
CMS Proposes New Payment Policy for IOPOs and HCLs
In keeping with ongoing efforts to intensify regulatory oversight of organ procurement organizations (OPOs) and curtail improper spending within federal health programs, the Centers for Medicare & Medicaid Services (CMS) recently issued a proposed rule that would, among other adjustments, align Medicare payment policies for non-renal organs to be consistent with those currently applicable to kidneys. If enacted as drafted, this latest rule could have a direct impact on the financial stability of OPOs and histocompatibility laboratories (HCL) at a time when such organizations face increasing pressure to meet CMS’s new outcome measures — or else face non-renewal or decertification later this year.
Client Alert | 2 min read | 04.23.26
Two Lawsuits in One: The Growing Risk of Pairing Biometric Tech With Wage-and-Hour Violations
Client Alert | 3 min read | 04.22.26
Client Alert | 10 min read | 04.22.26
The EU Industrial Accelerator Act Proposal’s Significance for the Automotive Industry
